AtriCure (ATRC) Q1 2026 earnings review
Profitability Inflection Reached, but PFA Headwinds Drag MIS Segment
AtriCure delivered a financially robust 26Q1, achieving GAAP operating profitability and nearly doubling Adjusted EBITDA YoY to $17.1 million. Revenue grew a stable 14.3% to $141.2 million, driven by rapid U.S. adoption of new products like the cryoSPHERE MAX and AtriClip FLEX-Mini. Gross margins expanded impressively by 246 bps to 77.4%. However, the minimally invasive (MIS) ablation segment remains a glaring concern, with U.S. revenue collapsing 25% YoY amid intense competition from Pulsed Field Ablation (PFA) catheters. Despite the massive Q1 margin beat, management maintained its full-year 2026 guidance, suggesting caution regarding ongoing hybrid ablation pressures and international macro headwinds.
🐂 Bull Case
Gross margin surged 246 basis points YoY to 77.4%, demonstrating exceptional pricing power and favorable product mix from newer, premium-priced devices.
U.S. Pain Management and Open Ablation grew 29.5% and 17.4% respectively, proving the surgical core remains highly insulated from catheter-based competition.
🐻 Bear Case
U.S. minimally invasive ablation fell 24.7% YoY to just $6.4 million, confirming that PFA catheter adoption by electrophysiologists continues to severely cannibalize hybrid procedures.
International revenue growth decelerated to 11.5% (down from 20%+ in H1 2025), suggesting lingering macro and reimbursement issues in key markets like the U.K.
⚖️ Verdict: 🟢
Bullish. The rapid transition to GAAP profitability and 77%+ gross margins proves AtriCure's business model is scaling efficiently. The weakness in MIS is well-documented and entirely offset by the accelerating core surgical franchises.
Key Themes
Gross Margin Acceleration
Gross margin leaped from 74.9% in 25Q1 to 77.4% in 26Q1. This accelerating trend is a powerful driver of operating leverage. Management attributes this to favorable product and geographic mix, heavily leaning on high-margin new products like the AtriClip FLEX-Mini and cryoSPHERE MAX. This mix shift is structurally elevating the company's profitability profile.
Pain Management Remains a High-Growth Engine
The Pain Management segment continues to print massive numbers, growing 29.5% YoY in the U.S. to $22.4 million. The launch of the cryoSPHERE MAX probe has fundamentally changed the adoption curve by cutting procedure times in half, cementing this franchise as a stable, multi-year growth pillar.
Open Ablation Resilience
Driven by the EnCompass clamp, U.S. Open Ablation grew a stable 17.4% YoY to $39.1 million. This confirms that AtriCure's core surgical ablation technology is successfully penetrating the untreated coronary bypass (CABG) market, unaffected by the PFA catheter wars happening in the EP lab.
Minimally Invasive (MIS) Segment Decelerating Further
The narrative that the MIS segment might bottom out is contradicted by the Q1 data. U.S. MIS Ablation reversed its trajectory deeper into the red, collapsing 24.7% YoY to $6.4 million. The technological innovation of Pulsed Field Ablation (PFA) catheters used by electrophysiologists is causing structural demand destruction for AtriCure's hybrid therapy. This remains the primary risk to overall top-line acceleration.
International Growth and Macro Headwinds
International revenue growth is decelerating, posting 11.5% YoY in 26Q1 compared to over 20% in the first half of 2025. This likely reflects the continued macro and reimbursement uncertainty with the U.K. National Health Service (NHS), a specific headwind flagged by management in late 2025 that appears to be capping overseas momentum.
Maintained Guidance Suggests Back-Half Conservatism or Risks
Despite a massive 95% YoY jump in Q1 Adjusted EBITDA to $17.1 million, management merely reiterated their full-year guidance of $80-$82 million. Historically, Q1 is the seasonal low for earnings. The refusal to raise guidance implies either extreme conservatism, planned R&D/SG&A spending spikes, or fear of further deterioration in the MIS segment.
Other KPIs
Reversing. A major milestone for the company, flipping from a $6.0 million operating loss in 25Q1 to a $0.5 million profit in 26Q1. This highlights strict cost discipline where SG&A and R&D are finally growing much slower than gross profit.
Stable. Grew 14.9% YoY, driven by the AtriClip FLEX-Mini. This is the company's largest segment and the bedrock of its recurring revenue base, showing no signs of slowing down despite new competitive entrants flagged in 2025.
Guidance
Stable. The midpoint of $605 million implies roughly 13.2% YoY growth compared to FY25 ($534.5 million). This signals management expects the current growth cadence to hold steady throughout the year, banking on core segment strength to cover the MIS weakness.
Accelerating. Implies a 31% YoY increase from FY25's $61.8 million. Achieving $17.1M in seasonally weak Q1 puts them on an excellent run rate to comfortably beat this guidance, barring unforeseen expense ramps.
Key Questions
EBITDA Guidance Conservatism
With gross margins jumping 246 bps in Q1 and Adjusted EBITDA nearly doubling YoY, why was the full-year EBITDA guidance of $80-$82 million merely maintained rather than raised? Are there significant R&D or commercial investments planned for later in the year?
Finding the Bottom in MIS
U.S. minimally invasive (MIS) ablation revenue hit a new low of $6.4 million. Have we found the absolute floor against PFA catheter competition, or does your internal modeling suggest further sequential erosion in 2026?
International Deceleration Causes
International growth decelerated to 11.5% this quarter. How much of this is attributable to the U.K. NHS funding headwinds highlighted last year, versus slower adoption of the EnCompass clamp in Europe?